Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Muik

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Journal of Virology|February 21, 2014
VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applicationsReinhard Tober, Zoltan Banki, Lisa Egerer, et al.
Molecular Therapy Oncolytics|October 15, 2016
Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapyCatherine Dold, Carles Rodriguez Urbiola, Guido Wollmann, et al.
Nature Communications|February 11, 2015
Off-target-free gene delivery by affinity-purified receptor-targeted viral vectorsRobert C Münch, Anke Muth, Alexander Muik, et al.
Journal of Virology|April 1, 2011
Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropismAlexander Muik, Inna Kneiske, Marina Werbizki, et al.
Vaccines|February 28, 2023
Toxicological Assessments of a Pandemic COVID-19 Vaccine-Demonstrating the Suitability of a Platform Approach for mRNA VaccinesCynthia M Rohde, Claudia Lindemann, Michael Giovanelli, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 24, 2013
Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1Tim Heinrich, Benjamin Rengstl, Alexander Muik, et al.
Science (New York, N.Y.)|January 30, 2021
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human seraAlexander Muik, Ann-Kathrin Wallisch, Bianca Sänger, et al.
Oncotarget|March 22, 2018
CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphomaJulia D S Hanauer, Benjamin Rengstl, Dina Kleinlützum, et al.
Cell Host & Microbe|March 4, 2022
Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2Hongjie Xia, Jing Zou, Chaitanya Kurhade, et al.
Nature Communications|June 23, 2022
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccineChaitanya Kurhade, Jing Zou, Hongjie Xia, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Journal of Virology|February 21, 2014
VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applicationsReinhard Tober, Zoltan Banki, Lisa Egerer, et al.
Molecular Therapy Oncolytics|October 15, 2016
Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapyCatherine Dold, Carles Rodriguez Urbiola, Guido Wollmann, et al.
Nature Communications|February 11, 2015
Off-target-free gene delivery by affinity-purified receptor-targeted viral vectorsRobert C Münch, Anke Muth, Alexander Muik, et al.
Journal of Virology|April 1, 2011
Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropismAlexander Muik, Inna Kneiske, Marina Werbizki, et al.
Vaccines|February 28, 2023
Toxicological Assessments of a Pandemic COVID-19 Vaccine-Demonstrating the Suitability of a Platform Approach for mRNA VaccinesCynthia M Rohde, Claudia Lindemann, Michael Giovanelli, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 24, 2013
Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1Tim Heinrich, Benjamin Rengstl, Alexander Muik, et al.
Science (New York, N.Y.)|January 30, 2021
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human seraAlexander Muik, Ann-Kathrin Wallisch, Bianca Sänger, et al.
Oncotarget|March 22, 2018
CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphomaJulia D S Hanauer, Benjamin Rengstl, Dina Kleinlützum, et al.
Cell Host & Microbe|March 4, 2022
Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2Hongjie Xia, Jing Zou, Chaitanya Kurhade, et al.
Nature Communications|June 23, 2022
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccineChaitanya Kurhade, Jing Zou, Hongjie Xia, et al.
Pageof 5